DCTH — DELCATH SYSTEMS, INC.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 872912 ·
Last close
$10.83
Market Cap
$373.87M
52W High
$12.27
52W Low
$8.48
ADV30
400,135
Next earnings
2026-08-06
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 24,994,000 21,258,000 -1,637,000 -1,070,000 124,838,000 41,313,000 12,128,000
Dec 2025 20,728,000 17,718,000 -2,184,000 -1,896,000 123,632,000 43,454,000 12,413,000
Sep 2025 20,563,000 17,939,000 -388,000 830,000 124,295,000 41,813,000 9,448,000
Jun 2025 24,156,000 20,838,000 2,590,000 2,697,000 116,876,000 34,421,000 11,890,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$22,516,000
Investing CF
$-26,590,000
Financing CF
$15,048,000
CapEx
$-1,547,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.07
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-528,848,000
Inventory
$10,252,000
Receivables
$12,939,000
ST Investments
$47,582,000
EBIT TTM
$660,000
Pretax Income TTM
$3,510,000
Interest Exp TTM
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$90,441,000
EBITDA
$-1,322,000
Free Cash Flow
$19,651,124
Enterprise Value
$285,477,440
Total Cash
$89,299,000
Total Debt
$907,000
Shares Out
34,521,647
Trailing EPS
$0.01
Book Value
$3.27
ROE
0.6%
ROA
-1.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 85,231,000 660,000 2,700,000 123,632,000 12,413,000 22,516,000
Dec 2024 37,205,000 -12,410,000 -26,386,000 76,589,000 7,843,000 -18,681,000
Dec 2023 2,065,000 -38,182,000 -47,678,000 38,613,000 22,836,000 -31,251,000
Dec 2022 2,719,000 -33,853,000 -36,508,000 17,862,000 23,721,000 -24,950,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.38

Peers — same industry

TickerNameMarket CapLastDaily %
CLPT ClearPoint Neuro, Inc. $354.48M $11.82
OFIX Orthofix Medical Inc. $394.92M $9.77
CV CapsoVision, Inc $330.76M $6.62
CARL CARLSMED, INC. $323.23M $11.89
ELMD Electromed, Inc. $317.13M $38.30

News headlines (Yahoo Finance, 1h cache)

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
2026-05-26 20:01 · Yahoo
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 20:01 · Yahoo
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
2026-05-12 12:00 · Yahoo
Delcath (DCTH) Q1 2026 Earnings Transcript
2026-05-08 16:25 · Yahoo
Delcath Systems Q1 Earnings Call Highlights
2026-05-07 17:42 · Yahoo
Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 15:15 · Yahoo
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
2026-05-07 12:00 · Yahoo
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
2026-05-07 11:00 · Yahoo
How The Delcath Systems (DCTH) Story Is Shifting With Hepzato Milestones And 2026 Guidance
2026-05-01 09:20 · Yahoo
Delcath Systems to Host First Quarter 2026 Earnings Call
2026-04-23 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.